Cybin (CYBN) Competitors $7.97 -0.07 (-0.87%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CYBN vs. MRVI, IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, PHAT, and UPBShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Its Competitors Maravai LifeSciences Iovance Biotherapeutics Urogen Pharma Tilray Brands Tango Therapeutics Stoke Therapeutics Prime Medicine Dianthus Therapeutics Phathom Pharmaceuticals Upstream Bio Cybin (NYSE:CYBN) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media prefer CYBN or MRVI? In the previous week, Maravai LifeSciences had 6 more articles in the media than Cybin. MarketBeat recorded 6 mentions for Maravai LifeSciences and 0 mentions for Cybin. Cybin's average media sentiment score of 1.00 beat Maravai LifeSciences' score of 0.90 indicating that Cybin is being referred to more favorably in the media. Company Overall Sentiment Cybin Positive Maravai LifeSciences Positive Do analysts prefer CYBN or MRVI? Cybin presently has a consensus target price of $85.00, indicating a potential upside of 964.50%. Maravai LifeSciences has a consensus target price of $6.64, indicating a potential upside of 147.26%. Given Cybin's stronger consensus rating and higher possible upside, equities analysts plainly believe Cybin is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more risk and volatility, CYBN or MRVI? Cybin has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Which has better valuation & earnings, CYBN or MRVI? Cybin has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$3.88-2.06Maravai LifeSciences$259.18M2.64-$144.85M-$1.14-2.36 Do institutionals and insiders believe in CYBN or MRVI? 17.9% of Cybin shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 2.1% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is CYBN or MRVI more profitable? Cybin has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Maravai LifeSciences -67.14%-12.91%-6.87% SummaryCybin beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$188.37M$778.94M$5.72B$21.10BDividend YieldN/A4.84%4.60%3.58%P/E Ratio-1.821.4028.0727.85Price / SalesN/A26.98462.5860.47Price / CashN/A19.5636.5523.00Price / Book0.746.808.644.69Net Income-$57.88M-$4.32M$3.24B$994.49M7 Day Performance-4.03%1.28%4.08%1.57%1 Month Performance-3.33%3.81%10.68%5.84%1 Year PerformanceN/A8.20%34.47%11.42% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin2.7079 of 5 stars$7.97-0.9%$85.00+966.5%N/A$188.01MN/A-1.8250MRVIMaravai LifeSciences3.6062 of 5 stars$2.67-2.2%$6.64+148.6%-67.3%$679.94M$259.18M-2.34610Options VolumeIOVAIovance Biotherapeutics4.6168 of 5 stars$2.01+7.5%$12.22+508.1%-64.0%$671.20M$164.07M-1.62500Analyst ForecastOptions VolumeGap UpHigh Trading VolumeURGNUrogen Pharma4.5082 of 5 stars$14.49+1.8%$32.86+126.8%+10.0%$668.13M$90.40M-4.56200TLRYTilray Brands1.8236 of 5 stars$0.66+13.1%$1.92+191.8%-60.7%$661.07M$788.94M-0.632,650Upcoming EarningsOptions VolumeTNGXTango Therapeutics1.6669 of 5 stars$6.09+2.7%$12.20+100.3%-31.9%$660.12M$40.99M-4.9990STOKStoke Therapeutics4.2453 of 5 stars$12.06+1.7%$24.75+105.2%-5.4%$658.48M$36.56M15.27100PRMEPrime Medicine3.853 of 5 stars$4.80+10.3%$10.08+110.1%-20.8%$645.57M$3.85M-2.34234Gap DownHigh Trading VolumeDNTHDianthus Therapeutics1.3859 of 5 stars$20.03-0.1%$53.00+164.6%-21.7%$644.17M$6.24M-6.9580Positive NewsPHATPhathom Pharmaceuticals4.31 of 5 stars$9.06-1.3%$17.50+93.2%-21.0%$632.48M$55.25M-1.73110Positive NewsUPBUpstream Bio1.7818 of 5 stars$11.73+2.2%$56.50+381.7%N/A$631.00M$2.30M0.0038News Coverage Related Companies and Tools Related Companies MRVI Competitors IOVA Competitors URGN Competitors TLRY Competitors TNGX Competitors STOK Competitors PRME Competitors DNTH Competitors PHAT Competitors UPB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CYBN) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYBN Stock Alerts